Cargando…

Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa

BACKGROUND: Even though nebulised administration of amikacin can achieve high epithelial lining fluid concentrations, this has not translated into improved patient outcomes in clinical trials. One possible reason is that the cellular and chemical composition of the epithelial lining fluid may inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heffernan, Aaron J., Sime, Fekade B., Lim, Sazlyna Mohd Sazlly, Naicker, Saiyuri, Andrews, Katherine T., Ellwood, David, Lipman, Jeffrey, Grimwood, Keith, Roberts, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017437/ https://www.ncbi.nlm.nih.gov/pubmed/33797739 http://dx.doi.org/10.1007/s40268-021-00344-5

Ejemplares similares

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
por: Avent, Minyon L., et al.
Publicado: (2022)

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis
por: Heffernan, Aaron, et al.
Publicado: (2021)

Challenges in Antifungal Therapy in Diabetes Mellitus
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2020)

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
por: Sime, Fekade Bruck, et al.
Publicado: (2016)

Morphological and Bactericidal Effects of Amikacin, Meropenem and Imipenem on Pseudomonas aeruginosa
por: Moghoofei, Mohsen, et al.
Publicado: (2015)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
por: Tang, Xi-kang, et al.
Publicado: (2022)

The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection
por: Yazdanian, Mohsen, et al.
Publicado: (2022)

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
por: Molinaro, Mariadelfina, et al.
Publicado: (2018)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa
por: Farhan, Sara Mahmoud, et al.
Publicado: (2021)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
por: Wang, Yuhang, et al.
Publicado: (2022)

Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia
por: Baharin, Janudin, et al.
Publicado: (2014)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa
por: Nageeb, Wedad M., et al.
Publicado: (2022)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?
por: Cuba, Gabriel T., et al.
Publicado: (2022)

Fatal Tenofovir-Associateacd Lactic Acidosis: A Case Report
por: Hashim, Hasriza, et al.
Publicado: (2015)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
por: Motos, Ana, et al.
Publicado: (2023)

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
por: Wong, Gloria, et al.
Publicado: (2014)

Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
por: Logre, Elsa, et al.
Publicado: (2020)

Evaluation of Synergistic Interactions Between Cell-Free Supernatant of Lactobacillus Strains and Amikacin and Genetamicin Against Pseudomonas aeruginosa
por: Aminnezhad, Sargol, et al.
Publicado: (2015)

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
por: Sime, Fekade Bruck, et al.
Publicado: (2012)

In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
por: Loho, Tonny, et al.
Publicado: (2018)

Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema: A case report
por: Chen, Tzu-Ting, et al.
Publicado: (2022)

Pharmacodynamic Model of the Dynamic Response of Pseudomonas aeruginosa Biofilms to Antibacterial Treatments
por: Roychowdhury, Swarnima, et al.
Publicado: (2023)

Acute coronary syndrome in young adults from a Malaysian tertiary care centre
por: Hoo, Fan Kee, et al.
Publicado: (2016)

Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain
por: Sime, Fekade B., et al.
Publicado: (2020)

Vaccination against respiratory Pseudomonas aeruginosa infection
por: Grimwood, Keith, et al.
Publicado: (2014)

In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-β-lactamase-producing Pseudomonas aeruginosa
por: Oie, Shigeharu, et al.
Publicado: (2009)

Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model
por: Zuluaga, Andres F., et al.
Publicado: (2015)

Concentration-Dependent Activity of Pazufloxacin against Pseudomonas aeruginosa: An In Vivo Pharmacokinetic/Pharmacodynamic Study
por: Umezaki, Yasuhiro, et al.
Publicado: (2022)

Combination Therapy of Polymyxin B and Amikacin for Community-Acquired Pseudomonas aeruginosa Pneumonia with MODS in a Previously Healthy Patient: A Case Report
por: Wang, Junyu, et al.
Publicado: (2021)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

Correlation of Aminoglycoside Consumption and Amikacin- or Gentamicin-Resistant Pseudomonas aeruginosa in Long-Term Nationwide Analysis: Is Antibiotic Cycling an Effective Policy for Reducing Antimicrobial Resistance?
por: Kim, Young Ah, et al.
Publicado: (2018)

Validation of a Malay Version of the Smartphone Addiction Scale among Medical Students in Malaysia
por: Ching, Siew Mooi, et al.
Publicado: (2015)

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2017)

Chronic pneumonia with Pseudomonas aeruginosa and impaired alveolar fluid clearance
por: Boyer, Sophie, et al.
Publicado: (2005)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
por: Kuti, Joseph L, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vm0892knpe651ltbqq1scghu7c